Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
21 Août 2024 - 4:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Shobie Ramakrishnan
|
b)
|
Position/status
|
Chief Digital and Technology Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
b)
|
Nature
of the transaction
|
Following the vesting on 19 August 2024 of 25% of an award made on
19 August 2019 under the GlaxoSmithKline Deferred Investment Award
Programme, Ms Ramakrishnan will receive a cash payment of
$99,026.66 less applicable tax withholding in respect of 2,385.035
notional ADSs.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$41.5200
|
2,385.035
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
Aggregated
volume
Price
|
|
e)
|
Date
of the transaction
|
2024-08-19
|
f)
|
Place
of the transaction
|
N/A
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: August
21, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
GSK (PK) (USOTC:GLAXF)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about GSK Plc (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur GSK Plc (PK)